Mylan Pharmaceuticals Inc. is recalling 33,893 vials of Rifampin for Injection, USP (600 mg/vial), an injectable antibiotic used to treat bacterial infections. The recall was issued after stability testing revealed that levels of a drug-related compound exceeded approved specifications, indicating the product is degrading faster than expected. While no incidents or injuries have been reported, the medication was distributed nationwide to hospitals and pharmacies.
The use of the affected medication may expose patients to higher-than-expected levels of drug impurities. This degradation can reduce the effectiveness of the antibiotic treatment or potentially cause unknown adverse health effects.
Hospital/Clinical return
Manufactured for Mylan Institutional LLC, Morgantown, WV
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.